Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vera Therapeutics Inc Cl A (NQ: VERA ) 43.44 -2.22 (-4.86%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Vera Therapeutics Inc Cl A < Previous 1 2 3 4 5 Next > Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday September 03, 2024 Via Benzinga VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024 August 08, 2024 VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday June 03, 2024 Via Benzinga Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market May 31, 2024 U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs. Via Benzinga Topics Economy Exposures Interest Rates Vera Therapeutics: Q4 Earnings Insights March 20, 2024 Via Benzinga (VERA) - Analyzing Vera Therapeutics's Short Interest January 31, 2024 Via Benzinga Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker May 29, 2024 NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 May 09, 2024 VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Could This Stock Be the Next Biotech Buyout? April 13, 2024 Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. Via The Motley Fool Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact April 11, 2024 Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... Via Benzinga Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options April 11, 2024 Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. Via Investor's Business Daily Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday April 11, 2024 We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! Via InvestorPlace Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket April 11, 2024 Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant... Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session April 10, 2024 Via Benzinga VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 March 20, 2024 VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace $10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying February 02, 2024 Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. Via Benzinga Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy January 26, 2024 72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile. Via Benzinga What's Going On With Vera Therapeutics Stock Today? January 26, 2024 Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals. Via Benzinga Exposures Product Safety Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 26, 2024 Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session January 26, 2024 Via Benzinga Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat) January 26, 2024 The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week. Via Benzinga Topics Government Exposures Political Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday January 26, 2024 U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Via Benzinga Topics Stocks Exposures US Equities Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings January 25, 2024 U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also... Via Benzinga Topics Stocks Exposures US Equities Why Is Immunology Disease Focused Vera Therapeutics Stock Trading Higher Today? January 25, 2024 Vera Therapeutics' 72-week data from Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR. Via Benzinga Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday January 25, 2024 U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings. Via Benzinga Topics Stocks Exposures US Equities Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 25, 2024 Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. Via Benzinga Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results January 25, 2024 U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 12 Health Care Stocks Moving In Thursday's Intraday Session January 25, 2024 Via Benzinga Why Vera Therapeutics Stock Soared by 22% This Week January 12, 2024 Executive changes and a bullish analyst take combined to boost sentiment on the company. Via The Motley Fool Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug December 21, 2023 The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... Via Benzinga Exposures Product Safety < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.